RUPINDERJIT SAMRA: Open Payments
NPI 1912139114 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$781 in 9 payments from 6 companies in 2025. Trend: 2023 $118 · 2024 $670 · 2025 $781
Food & beverage: $781
| Company | Payments | Amount |
|---|---|---|
| Tandem Diabetes Care, Inc. | 2 | $196 |
| AstraZeneca Pharmaceuticals LP | 1 | $144 |
| Novo Nordisk Inc | 1 | $123 |
| ALK-Abello, Inc | 1 | $119 |
| Alkermes, Inc. | 1 | $114 |
| CORDIS US CORP. | 3 | $84 |
Products named: t:slim X2 Insulin Pump with Control-IQ, TEZSPIRE, VIVITROL, INFINITI, MYNX CONTROL VENOUS, MYNX CONTROL.
Industry payments across CA — which companies pay providers there.
